Chanqi Ye

Chanqi Ye

Auto-generated profile, based on publicly available information

Chanqi Ye

Department of Medical Oncology, The First Affiliated Hospital, School of Medicine, Zhejiang University and Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Hangzhou, Zhejiang Province, People's Republic of China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
XBXuanwen Bao
Xuanwen Bao
QLQiong Li
Qiong Li
JCJinzhang Chen
Jinzhang Chen
DCDiyu Chen
Diyu Chen
CYChanqi Ye
Chanqi Ye
Jian RuanJian Ruan
Jian Ruan
Intrahepatic cholangiocarcinoma (ICC) is a relatively rare but highly aggressive tumor type that responds poorly to chemotherapy and immunotherapy. Comprehensive molecular characterization of ICC is essential for the development of novel therapeutics. Here, we constructed two independent cohorts from two clinic centers. A comprehensive multiomics analysis of ICC via proteomic, whole-exome sequencing (WES), and single-cell RNA sequencing (scRNA-seq) was performed. Novel ICC tumor subtypes were derived in the training cohort (n = 110) using proteomic signatures and their associated activated pathways, which were further validated in a validation cohort (n = 41). Three molecular subtypes, chromatin remodeling, metabolism, and chronic inflammation, with distinct prognoses in ICC were identified. The chronic inflammation subtype was associated with a poor prognosis. Our random forest algorithm revealed that mutation of lysine methyltransferase 2D (KMT2D) frequently occurred in the metabolism subtype and was associated with lower inflammatory activity. scRNA-seq further identified an APOE+C1QB+ macrophage subtype, which showed the capacity to reshape the chronic inflammation subtype and contribute to a poor prognosis in ICC. Altogether, with single-cell transcriptome-assisted multiomics analysis, we identified novel molecular subtypes of ICC and validated APOE+C1QB+ tumor-associated macrophages as potential immunotherapy targets against ICC.

4 April 2023
Verified
Other
Open access
XBXuanwen Bao
Xuanwen Bao
QLQiong Li
Qiong Li
JCJinzhang Chen
Jinzhang Chen
DCDiyu Chen
Diyu Chen
CYChanqi Ye
Chanqi Ye
Jian RuanJian Ruan
Jian Ruan
Supplementary Figure from Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis

4 April 2023
Verified
Other
Open access
XBXuanwen Bao
Xuanwen Bao
QLQiong Li
Qiong Li
JCJinzhang Chen
Jinzhang Chen
DCDiyu Chen
Diyu Chen
CYChanqi Ye
Chanqi Ye
Jian RuanJian Ruan
Jian Ruan
Intrahepatic cholangiocarcinoma (ICC) is a relatively rare but highly aggressive tumor type that responds poorly to chemotherapy and immunotherapy. Comprehensive molecular characterization of ICC is essential for the development of novel therapeutics. Here, we constructed two independent cohorts from two clinic centers. A comprehensive multiomics analysis of ICC via proteomic, whole-exome sequencing (WES), and single-cell RNA sequencing (scRNA-seq) was performed. Novel ICC tumor subtypes were derived in the training cohort (n = 110) using proteomic signatures and their associated activated pathways, which were further validated in a validation cohort (n = 41). Three molecular subtypes, chromatin remodeling, metabolism, and chronic inflammation, with distinct prognoses in ICC were identified. The chronic inflammation subtype was associated with a poor prognosis. Our random forest algorithm revealed that mutation of lysine methyltransferase 2D (KMT2D) frequently occurred in the metabolism subtype and was associated with lower inflammatory activity. scRNA-seq further identified an APOE+C1QB+ macrophage subtype, which showed the capacity to reshape the chronic inflammation subtype and contribute to a poor prognosis in ICC. Altogether, with single-cell transcriptome-assisted multiomics analysis, we identified novel molecular subtypes of ICC and validated APOE+C1QB+ tumor-associated macrophages as potential immunotherapy targets against ICC.

4 April 2023
Verified
Other
Open access
XBXuanwen Bao
Xuanwen Bao
QLQiong Li
Qiong Li
JCJinzhang Chen
Jinzhang Chen
DCDiyu Chen
Diyu Chen
CYChanqi Ye
Chanqi Ye
Jian RuanJian Ruan
Jian Ruan
Supplementary Figure from Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis

4 April 2023
Verified
Other
Open access
XBXuanwen Bao
Xuanwen Bao
QLQiong Li
Qiong Li
JCJinzhang Chen
Jinzhang Chen
DCDiyu Chen
Diyu Chen
CYChanqi Ye
Chanqi Ye
Jian RuanJian Ruan
Jian Ruan
Supplementary Figure from Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis

4 April 2023
Verified
Other
Open access
XBXuanwen Bao
Xuanwen Bao
QLQiong Li
Qiong Li
JCJinzhang Chen
Jinzhang Chen
DCDiyu Chen
Diyu Chen
CYChanqi Ye
Chanqi Ye
Jian RuanJian Ruan
Jian Ruan
Supplementary Figure from Molecular Subgroups of Intrahepatic Cholangiocarcinoma Discovered by Single-Cell RNA Sequencing–Assisted Multiomics Analysis